Table III.
Lung cancer risk associated with significant SNPs in the discovery and in the replication populations
| Discovery population | Replication population | Pooled population | ||||||
|---|---|---|---|---|---|---|---|---|
| Gene name | SNP | Model | OR a (95% CI) | P value | OR a (95% CI) | P value | OR a (95% CI) | P value |
| Bcl-2 | rs1462129 | Additive | 1.30 (1.08–1.55) | 0.0046 | 1.11 (0.98–1.25) | 0.098 | 1.16 (1.05–1.28) | 0.002 |
| rs2551402 | Additive | 1.30 (1.08–1.55) | 0.0048 | 1.10 (0.97–1.24) | 0.119 | 1.16 (1.05–1.27) | 0.003 | |
| CASP9 | rs6685648 | Additive | 1.17 (0.97–1.42) | 0.102 | 1.14 (1.00–1.31) | 0.046 | 1.16 (1.04–1.28) | 0.005 |
| ANKS1B | rs1549102 | Additive | 0.80 (0.67–0.96) | 0.016 | 0.86 (0.75–0.97) | 0.014 | 0.85 (0.77–0.94) | 0.001 |
| rs11110099 | Additive | 1.19 (0.99–1.43) | 0.057 | 1.16 (1.03–1.32) | 0.018 | 1.16 (1.06–1.28) | 0.002 | |
| rs10745877 | Recessive | 1.60 (1.08–2.36) | 0.019 | 1.43 (1.08–1.90) | 0.013 | 1.42 (1.15–1.77) | 0.001 | |
Significant ORs in boldface.
aAdjusted by age, gender, smoking status and pack year of smoking, asbestos exposure, lung cancer in first degree relatives, prior history of emphysema and hay fever where appropriate.